CD86 and neoplasm: The results showed that the RFS was correlated with tumour size (P =.004), tumour differentiation (P =.011), T stage (P =.017), TNM stage (P =.023), lymph node metastasis (P =.019), CD86 protein expression (P =.002), CD163 protein expression (P =.001), co‐expression of CD68 and CD86 (P =.011) and co‐expression of CD68 and CD163 (P =.016) (Table 1).